IGC PharmaIGC +0.59%29 Days Payable is 395.13 as of Mar. 2026, which is 19% above its 10-year median of 332.46. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Fairly Valued). The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, IGC Pharma ranks better than 75.67% on this metric.
IGC Pharma's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.13 Mil. IGC Pharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.26 Mil.
Hence, IGC Pharma's Days Payable for the
three
months ended in Mar. 2026 was 395.13.
The historical rank and industry rank for IGC Pharma's Days Payable or its related term are showing as below:
IGC'
s Days Payable Range Over the Past 10 Years
Min: 16.72 Med: 332.46 Max: 1309.86
Current: 412.53
During the past 13 years, IGC Pharma's highest Days Payable was 1309.86. The lowest was 16.72. And the median was 332.46.
IGC's Days Payable is ranked better than 75.67% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs IGC: 412.53
IGC Pharma's Days Payable
declined
from Mar. 2025 (445.36) to Mar. 2026 (395.13).
It may suggest that IGC Pharmaaccelerated paying its suppliers.
IGC Pharma Days Payable Related Terms
IGC Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for IGC Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
IGC Pharma's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a Days Payable of 395.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IGC Pharma and its competitors. This is 19% above median its historical median of 332.46. Over the past decade, IGC Pharma's Days Payable has ranged from 16.72 to 1,309.86. According to the industry distribution chart, IGC Pharma ranks #172 out of 707 companies in the Biotechnology industry, placing it in the top 24.3%.
Is IGC Pharma's Days Payable too high?
IGC Pharma's current Days Payable of 395.13 is 19% above median its 10-year median of 332.46. Over the past 10 years, this metric has ranged from a low of 16.72 to a high of 1,309.86. The Biotechnology industry median Days Payable is 113.76. IGC Pharma's value of 395.13 is 247.3% above this industry median. Based on the distribution chart, IGC Pharma ranks #172 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Days Payable compare to CRVO and NEUP?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #172 out of 707 companies for Days Payable. This places IGC Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. IGC Pharma's value of 395.13 is 247.3% above this benchmark. Historically, IGC Pharma's own Days Payable has ranged from 16.72 to 1,309.86 over the past decade. While the company's 10-year median is 332.46 vs. the industry median of 113.76, IGC Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Days Payable of 395.13 is 247.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on IGC Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Days Payable is 395.13, which is 19% above median its own 10-year median of 332.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 9.8% above its estimated fair value. The current Days Payable is 395.13, which is 19% above median its 10-year median of 332.46 and 247.3% above the Biotechnology industry median of 113.76. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For IGC Pharma (IGC), the current Days Payable is 395.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.26 is trading 9.8% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Fairly Valued.
Key valuation signals for IGC:
Days Payable: 395.13 (19% above median its 10-year median of 332.46)
GF Value™: $0.24 vs. price of $0.26 (9.8% above fair value)
Industry Position: 247.3% above the Biotechnology median (#172 of 707)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score
Get the complete analysis for IGC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
